HC Wainwright & Co. Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)

Market Context

Mineralys Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $22.24 with a market capitalization of $2.4B. The stock has declined 37.7% over the past 52 weeks.

Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Mineralys Therapeutics, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Mineralys Therapeutics, Inc.

Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Oct 12, 2026	UBS	Neutral	N/A
Oct 12, 2026	HC Wainwright & Co.	Buy	N/A
Apr 27, 2026	TD Cowen	Buy	N/A
Mar 13, 2026	B of A Securities	Buy	N/A
Dec 19, 2025	Stifel	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View MLYS Stock Page